April 2 (Reuters) - The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's NVAX.O COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.